Loading…
Based on limited metadata, the FDA issued a Warning Letter to Celltrion Inc., a biopharmaceutical manufacturer, on January 26, 2018. Without access to the full letter text or specific subject line, the precise nature of the violations cannot be determined from the available information. The warning falls under FDA's regulatory authority for drug products, though the specific product type and issuing office are not indicated in the metadata provided. To understand the actual compliance issues cited, the complete Warning Letter would need to be reviewed.